{"conversation_id": "1259161485458235392", "entities": {"mentions": [{"start": 0, "end": 12, "username": "nytpolitics", "id": "14434063"}], "hashtags": [{"start": 256, "end": 267, "tag": "leronlimab"}, {"start": 268, "end": 276, "tag": "covid19"}], "urls": [{"start": 232, "end": 255, "url": "https://t.co/5YNlD8IIIG", "expanded_url": "https://www.targetedonc.com/view/leronlimab-shows-further-promise-for-covid-19-treatment-study-shows", "display_url": "targetedonc.com/view/leronlima\u2026"}]}, "id": "1259498586808541187", "in_reply_to_user_id": "14434063", "created_at": "2020-05-10T15:00:38.000Z", "possibly_sensitive": false, "author_id": "999664767852625920", "reply_settings": "everyone", "text": "@nytpolitics To disseminate results that can inform the public health in response to COVID-19, CytoDyn announced these findings in a pre-print manuscript, which has been submitted for publication and is currently under peer review.\nhttps://t.co/5YNlD8IIIG #leronlimab #covid19", "public_metrics": {"retweet_count": 0, "reply_count": 0, "like_count": 0, "quote_count": 0}, "referenced_tweets": [{"type": "replied_to", "id": "1259161485458235392"}], "lang": "en", "context_annotations": [{"domain": {"id": "123", "name": "Ongoing News Story", "description": "Ongoing News Stories like 'Brexit'"}, "entity": {"id": "1220701888179359745", "name": "COVID-19"}}, {"domain": {"id": "47", "name": "Brand", "description": "Brands and Companies"}, "entity": {"id": "10040666972", "name": "The New York Times"}}, {"domain": {"id": "29", "name": "Events [Entity Service]", "description": "Entity Service related Events domain"}, "entity": {"id": "1219057585707315201", "name": "COVID-19: Latest news updates from around the world", "description": "This page is a timeline of Tweets with the latest information and updates on COVID-19 from experts, journalists, health authorities and other trusted sources from around the world. For more on COVID-19, visit: twitter.com/explore/tabs/covid-19"}}], "source": "Twitter for Android"}